BioNTech To Exit Operations At Curevac's Sites, Sites In Idar-Oberstein, Marburg, Singapore

May 5 (Reuters) - BIONTECH SE 22UAy.DE:

• TO EXIT OPERATIONS AT CUREVAC'S SITES, SITES IN IDAR-OBERSTEIN, MARBURG, SINGAPORE

• OPERATIONS IN IDAR-OBERSTEIN, MARBURG, TUEBINGEN TO CEASE BY END OF 2027, SINGAPORE OPERATIONS TO END IN Q1 2027

• PLANT CLOSURES TO AFFECT AROUND 1,860 JOBS

• EXPLORING OPTIONS FOR DIVESTMENTS OF EACH SITE, INCLUDING PARTIAL OR TOTAL SALE

• EXPECTS RECURRING ANNUAL SAVINGS OF AROUND EUR 500 MLN UPON FULL IMPLEMENTATION OF COST SAVING MEASURES IN 2029

• COST SAVINGS TO SUPPORT CAPITAL ALLOCATION TO ADVANCE ONCOLOGY PIPELINE TOWARD COMMERCIALIZATION

• PLANS SHARE BUYBACK OF AMERICAN DEPOSITARY SHARES UP TO $1 BILLION OVER NEXT 12 MTHS

• SHARE BUYBACK TO SATISFY OBLIGATIONS IN THE ORDINARY COURSE OF BUSINESS

• Q1 REVENUES EUR 118.1 MILLION (Q1 2025: EUR 182.8 MILLION)

• Q1 NET LOSS EUR 531.9 MILLION (Q1 2025: EUR 415.8 MILLION)

• CONFIRMS 2026 GUIDANCE

Further company coverage: [22UAy.DE]